scholarly journals Analysis of gene expression patterns in triple negative breast cancer III: the retinoic acid receptor alpha and other TNBC candidate genes.

2021 ◽  
Author(s):  
Shahan Mamoor

Triple negative breast cancer (TNBC) shares overlap with the basal or basal-like molecular subtype of breast cancer and is more frequently diagnosed in women of African descent (black women) for reasons not understood (1, 2). To understand genes whose expression may be of pertinence to the development or progression of triple negative breast cancer, we mined published microarray data (3) comparing global gene expression profiles of TNBC cases, identifying genes whose expression was least different among TNBC cases, indicating conservation of expression patterns suggestive of importance for TNBC biology. We identified the gene encoding the retinoic acid receptor alpha (RARA), a fatty acid elongase (ELOVL1), as well as multiple genes encoding molecules involved in epigenetic functions or with nucleic acid binding or modification properties, including TDRD7, KDM1B, PHF7, TAF5L, as well as the microRNA hsa-miR-605. Kaplan-Meier survival analysis revealed that expression levels of each of these genes correlated with survival outcomes in the basal subtype of human breast cancer, which shares significant overlap with triple negative breast cancer at the level of gene expression (2). RARA, ELOVL1, TDRD7, KDM1B, PHF7, TAF5L and hsa-miR-605 may be of relevance in understanding the etiology or progression of triple negative breast cancer. Together with our previous findings, the data allude to a potential pathogenic mechanism involving transcriptional perturbation of epigenetic machinery in triple negative breast cancer (4, 5).

2013 ◽  
Vol 4 (1) ◽  
Author(s):  
Henrik J. Johansson ◽  
Betzabe C. Sanchez ◽  
Filip Mundt ◽  
Jenny Forshed ◽  
Aniko Kovacs ◽  
...  

2020 ◽  
Author(s):  
Shahan Mamoor

Treatment with trastuzumab has been associated with an increased risk of central nervous system metastasis in patients with human breast cancer (1-5). We performed unbiased transcriptome profiling of primary tumors of patients treated with trastuzumab using published microarray and multiplexed gene expression datasets (6, 7) to understand the transcriptional makeup of breast tumors in the trastuzumab-treated patients. We found that the retinoid acid receptor alpha was among the genes most differentially expressed in the primary tumors of patients treated with trastuzumab; retinoid acid receptor alpha was expressed at significantly higher levels in tumors from patients with trastuzumab as compared to those not treated with trastuzumab. Increased retinoic acid receptor alpha expression is known to confer tamoxifen resistance to human breast cancers (8), and RARA expression is higher in tumors with higher proliferative capacity (9), suggesting that trastuzumab could contribute to resistance to endocrine therapy.


2014 ◽  
Vol 61 (11) ◽  
pp. 1105-1114 ◽  
Author(s):  
Akira Uruno ◽  
Akiko Saito-Hakoda ◽  
Atsushi Yokoyama ◽  
Naotaka Kogure ◽  
Ken Matsuda ◽  
...  

Author(s):  
Siyue Lou ◽  
Hang Gao ◽  
Huanwu Hong ◽  
Zhihui Zhu ◽  
Huajun Zhao

Abstract Background Retinoids are promising agents in the treatment of different types of neoplasia including estrogen receptor-positive breast cancers, whereas refractoriness/low sensitivity is observed in triple-negative breast cancer (TNBC) subtype. However, the reason for these diverse retinoid-sensitivity remains elusive. Methods Determinants of retinoid sensitivity were investigated using immunohistochemistry of primary patient samples, and identified retinoic acid receptor α (RARα) as a putative factor. The anti-tumor activity of hypo-phosphorylated RARα was investigated in TNBC cell models and a xenograft mouse model. Next, miRNA sequencing analysis was performed to identify the target miRNA of RARα, and luciferase reporter was used to confirm the direct target gene of miR-3074-5p. Results We discovered that serine-77 residue of RARα was constantly phosphorylated, which correlated with TNBC’s resistance to retinoids. Overexpression of a phosphorylation-defective mutant RARαS77A mimicked activated RARα and repressed TNBC cell progression both in vitro and in vivo, via activating cell cycle arrest, apoptosis, and cytotoxic autophagy, independent of RARα agonists. We further revealed that the anti-tumor action of RARαS77A was, at least in part, mediated by the up-regulation of miR-3074-5p, which directly targeted DHRS3, a reductase negatively associated with TNBC patient survival. Our results suggest that the inhibition of RARαS77 phosphorylation by either expressing RARαS77A or inhibiting RARα’s phosphokinase CDK7, can bypass RA stimuli to transactivate tumor-suppressive miR-3074-5p and reduce oncogenic DHRS3, thus overcoming the RA-resistance of TNBC. Conclusion The novel regulatory network, involving RARαS77 phosphorylation, miR-3074-5p, and DHRS3, emerges as a new target for TNBC treatment.


2013 ◽  
Vol 13 (5) ◽  
pp. 401-408 ◽  
Author(s):  
Samar Alsafadi ◽  
Caroline Even ◽  
Coralie Falet ◽  
Aicha Goubar ◽  
Frédéric Commo ◽  
...  

2017 ◽  
pp. 271-285
Author(s):  
Ganesan Padmavathi ◽  
Javadi Monisha ◽  
Anand Anip ◽  
Krishan Kumar Thakur ◽  
Ajaikumar B. Kunnumakkara

Sign in / Sign up

Export Citation Format

Share Document